Business Wire

GCCA

30.3.2022 08:02:04 CEST | Business Wire | Press release

Share
GCCA: Cement and Concrete Industry Launches Net Zero Accelerators Across the World – Including Focus on the ‘Global South’

The Global Cement and Concrete Association (GCCA) has today launched a series of Net Zero Accelerator initiatives to help national cement and concrete industries decarbonise in line with the GCCA’s 2050 Net Zero Global Industry Roadmap.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220329005500/en/

The first wave of Accelerators will launch in Egypt, which later this year will be the host country for COP27, as well as in India, Thailand and Colombia. These countries combined represent approximately 10% of global cement and concrete production. Concrete, a local and durable material, is fundamental to overcoming sustainable development challenges which many parts of the world are facing, such as population growth, increasing urbanisation and the need for more resilient infrastructure and communities in the face of a rapidly changing climate.

Globally, cement and concrete manufacture accounts for around 7% of CO2 emissions. The global plan to eliminate these emissions by 2050 requires all parts of the world to accelerate the reductions in CO2 emissions. The Accelerator program will identify the barriers to decarbonisation in target countries and recommend key actions. This includes encouraging government policies that can have an immediate impact, such as better recycling, the use of waste as an alternative to fossil fuels, and other circular economy practices. It will also include identifying lighthouse projects that can fully eliminate emissions over the next decades, such as carbon capture utilisation and storage technologies.

Thomas Guillot, GCCA Chief Executive, said: “Last year our industry made a breakthrough net zero global commitment. This is the next logical step as we move our focus from a global roadmap to driving decisive local action.

“Concrete will continue to be the world’s most used building material for decades to come, meaning global cooperation between governments and industry is crucial to ensuring net zero targets are met. Our Net Zero Accelerators will offer collaboration and support to a number of target countries to help them decarbonise and align with the global roadmap. I’m proud to launch the first phase of the Accelerator program to assist these nations in embracing greener technologies and work towards a more sustainable future together. I now call on more partners around the world to join us and be part of this movement.”

His Excellency, Dr Mahmoud Mohieldin, COP 27 UNFCCC High-Level Champion of Egypt, said: “Much of the infrastructure the world needs to overcome our major global challenges – such as alleviating poverty, the need for clean water and energy, and safe, affordable housing – is yet to be built.

“Cement and concrete will play a critical role in delivering a healthier, more resilient, zero carbon world as the industry moves to rapidly and fully decarbonise. As such, we are pleased to support the Net Zero Accelerator initiative, helping developing countries achieve their decarbonisation targets, as we work to support all industries and countries with their climate ambitions to help build a more sustainable future for all. The full and willing participation of a sector which accounts for 7-8% of global CO2 emissions is critical to contribute to the goal of the 2015 Paris Climate Change Agreement to limit global warming well below 2°C degrees and as close as possible to 1.5°C.”

The accelerator programme comprises three elements – i. net zero national roadmaps including emissions forecasts, reduction levers, policy needs and the industry commitment; ii. identification and funding exploration for large scale carbon cutting ‘Lighthouse’ Projects; and iii. policy dialogues with national governments to help accelerate the transition.

The GCCA is partnering with the cement and concrete industry on the ground and will work closely with policymakers, designers, and the construction sector to help overcome procurement and resourcing challenges, as well as demonstrate the business case for greener technologies to be used on a wider scale.

The Accelerators will help align Phase 1 countries’ cement and concrete industries with the GCCA’s 2050 Net Zero Roadmap , which marked the biggest global commitment by a heavy industry to decarbonise when it was launched last year. The Roadmap sets out a path to fully decarbonise by 2050, a target aligned with the Paris Agreement to limit global warming to 1.5°C. The roadmap actions between now and 2030, to reduce concrete related emissions by 25%, will prevent almost 5 billion tonnes of carbon from entering the atmosphere compared to a business-as-usual scenario.

Lighthouse Projects and a new tranche of phase two Accelerators will be announced later this year.

-ends-

Notes to editors:

About the GCCA:

Launched in January 2018, the Global Cement and Concrete Association (GCCA) is dedicated to developing and strengthening the sector’s contribution to sustainable construction. The GCCA aims to foster innovation throughout the construction value chain in collaboration with industry associations as well as architects, engineers, and innovators. In this way, the association demonstrates how concrete solutions can meet global construction challenges and sustainable development goals while showcasing responsible industrial leadership in the manufacture and use of cement and concrete. The GCCA is headquartered in London, England. It complements and supports the work done by associations at the national and regional levels.

The GCCA works with key a range of partners. It co-leads the Mission Possible Partnership’s Concrete Action for Climate initiate with the World Economic Forum. The GCCA is also an official accelerator for the Race to Zero.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye